Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses May have been Affected by Fraud; Contact BFA Law (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for potential violations of federal securities laws following the sudden resignation of its auditor, CohnReznick LLP. This event has triggered a drastic stock price drop of more than 20% as of October 10, 2024. Investors are encouraged to seek more information and may have legal recourse. The law firm has a notable history of representing plaintiffs in securities class actions, which adds a layer of concern for current shareholders.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics faced a significant stock price decline of over 20% following the resignation of its independent auditor.
  • There are potential violations of federal securities laws prompting an investigation, which could have serious legal repercussions.
  • The negative developments may affect investor confidence and the company's market reputation.

Full Press Release Details

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What prompted the investigation into ADMA Biologics?

The investigation was prompted by potential violations of federal securities laws.

Why did ADMA Biologics's stock fall recently?

The stock fell following the unexpected resignation of its auditor, CohnReznick LLP.

What was the stock decline percentage on October 10, 2024?

ADMA Biologics's stock declined by more than 20% during trading on October 10.

How does Bleichmar Fonti & Auld LLP charge clients?

They operate on a contingency fee basis, meaning no costs unless approved by court.

What notable recoveries has BFA achieved recently?

BFA recovered over $900 million from Tesla's Board and $420 million from Teva.

Last updated: Nov 8, 2024